CADM1: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of CADM1. The page also collects GeneMedi's different modalities and formats products for CADM1 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the CADM1 target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Transmembrane Protein.
Enables signaling receptor binding activity. Involved in several processes, including cell recognition; positive regulation of cytokine production; and susceptibility to natural killer cell mediated cytotoxicity. Located in plasma membrane. Implicated in breast carcinoma and prostate cancer. Biomarker of cervix uteri carcinoma in situ. [provided by Alliance of Genome Resources, Apr 2022]
| Target ID | GM-MP0174 |
| Target Name | CADM1 |
| Gene ID | 23705,54725,363058,695983,479432,101083958,529873,100062374 |
| Gene Symbol and Synonyms | 2900073G06Rik,3100001I08Rik,BL2,CADM1,IGSF4,IGSF4A,Necl-2,NECL2,RA175,RA175A,RA175B,RA175C,RA175N,sgIGSF,ST17,sTSLC-1,SYNCAM,SYNCAM-1,synCAM1,TSLC-1,TSLC1 |
| Uniprot Accession | Q9BY67,Q6AYP5 |
| Uniprot Entry Name | CADM1_HUMAN,CADM1_RAT |
| Protein Sub-location | Transmembrane Protein |
| Category | |
| Disease | Ovary Cancer, Ovarian cancer, Malignant neoplasm of bladder |
| Gene Ensembl | ENSG00000182985 |
| Target Classification | N/A |
Pre-made anti-CADM1 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-CADM1 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-CADM1 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Antibody Name | Species | Format | Classified by tag | Detail |
| Anti-CADM1 monoclonal antibody | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | mab | FACS/Biofunctional Antibody | Detail |
Multi-species CADM1/ BL2/ IGSF4 VLP (virus-like particle) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine CADM1 VLP (virus-like particle) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
| Products Name | Species | Expression Platform | Detail |
| CADM1 VLP (virus-like particle) | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | Mammalian cell | Products Developing |